Project description
New database to help treat type 2 diabetes
Type 2 diabetes is the most common type of diabetes, accounting for around 90 % of all cases. It is most commonly diagnosed in older adults, but is increasingly being seen in children, adolescents and younger adults due to rising levels of obesity, physical inactivity and poor diet. Delivering high-quality patient-centred care and a personalised approach to disease management is necessary. The EU-funded EASY-Diabetes project is developing a digital health solution to ensure patients receive the most appropriate therapy. Its software-as-a-service works by providing healthcare providers access to a curated global database of clinical data and medical evidence collected over the course of nine years. Powered by machine learning algorithms and artificial intelligence, the project is preparing its go-to-market strategy.
Objective
EASY – Diabetes is a digital health solution that helps patients with Type 2 diabetes and health care providers analyse data
and make better decisions about therapies by accessing a carefully curated global database based on clinical data and
medical evidence collected over the course of nine years and powered by machine learning algorithms and other forms of
artificial intelligence. We offer EASY-Diabetes as a Software-as-a-Service to healthcare providers at a fee of €50 per patient
per year.
Diabetes is a prevalent and costly chronic disease, affecting 425 million people worldwide. Although 9.2% of the health care
budget in Europe spent on diabetes, the results for patients remain inadequate even in the most advanced healthcare
systems. Patients lack a patient-centred and personalised approach to disease management. 90% of patients with T2D are
treated by GPs in primary care. Most clinics lack both the manpower and the expertise required to deal with the needs of
patients for regular contact with health care providers and the complexity of diabetes treatment. Existing eHealth solutions
show some crucial drawbacks, such as lack of clinical validation against the standard of care, no personalised medical
treatment options, not being drug agnostic.
Our team brings together demonstrated expertise in medicine, clinical trials, drug development, regulatory affairs, product
development, programming, machine learning, business development.
The SME Phase 1 Feasibility study will aim to complete the validation of the commercial feasibility of Easy – Diabetes with
target market segments and key stakeholders. We will strengthen our financial planning and IP protection strategy
necessary to improve our service and refine our go-to-market strategy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth scienceshealth care serviceseHealth
- natural sciencescomputer and information sciencesdatabases
- medical and health sciencesclinical medicineendocrinologydiabetes
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Call for proposal
(opens in new window) H2020-EIC-SMEInst-2018-2020
See other projects for this callSub call
H2020-SMEInst-2018-2020-1
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
22229 LUND
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.